Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Trial Profile

Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Bavituximab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 03 May 2017 Status changed from planning to not yet recruiting.
    • 13 Mar 2017 This trial is on track to be initiated by mid-calendar 2017, according to a Peregrine Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top